Design Therapeutics, Inc. — Form 10-Q
Filed August 3, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On May 1, 2026, Design Therapeutics and Wisconsin Alumni Research Foundation (WARF) executed a First Amendment to their Human Therapeutics Exclusive License Agreement (originally dated February 20, 2019). The substantive amendments to Section 3C(ii) and the underlying rationale are entirely redacted as confidential. No dollar amounts, royalty rates, milestone payments, territory restrictions, or other material economic or operational terms are disclosed in the filing.
Why this rating
Amendment exists but core terms redacted; cannot assess materiality. Routine IP agreement modification insufficient for scoring without disclosed financial or operational impact.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.